'Progressive ms' diaporamas de présentation

Multiple Sclerosis: A neurodegenerative autoimmune disease

Multiple Sclerosis: A neurodegenerative autoimmune disease. Overview Pathophysiology Prevalence Research ongoing. A chronic autoimmune disorder that progressively robs sufferers of cognitive function, the ability to sense the world around them, and the capacity to walk. P. Martini.

1.1k views • 49 slides

Looking Into the Crystal Ball

Looking Into the Crystal Ball. Promising Research in Multiple Sclerosis Treatment. What do we need to study in MS?. Why do people get MS? Why do people get different types of MS? Why does the course of MS vary so much? What actual cells are abnormal in MS?

536 views • 38 slides

LDN Prescribing And Research In Scotland

450 views • 38 slides

Recent Studies Funded by the Progressive MS Alliance

Recent Studies Funded by the Progressive MS Alliance. Tim Coetzee, PhD ACTRIMS 2016. Disclosures. TC is an employee of the National MS Society The National MS Society is founding member of the Progressive MS Alliance. Outline. Overview of the Alliance Collaborative Network Awards Update

305 views • 30 slides

Regional Update

Regional Update. Financial Report. Governance Report. Dr. Joel Pachter Progressive MS Update. Leukocytes enter the CNS during neuroinflammation. The blood-brain barrier is damaged during EAE/MS. Urgent Need to Find Solutions for People with Progressive MS.

326 views • 19 slides

Multiple Sclerosis

Multiple Sclerosis . Allyson Bortoletto 3/6/14 Tara Holloway Psychology . Definition of multiple sclerosis . Multiple sclerosis is a disease that immune system in your body eats the protective sheath (myelin) that covers your nerves.

922 views • 9 slides

Multiple Sclerosis

Multiple Sclerosis. By: Julie Carrasco, Brianna Macias, Alexx Rusake. Origin. Discovered by Jean-Martin Charcot in 1868 Recognized in 1873 by Dr. Walter Moxon in England and in 1878 by Dr. Edward Seguin in the U.S. Quick Intro.

198 views • 8 slides

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment. Supplemental Slides. Dalfampridine Phase III Trials Responder Analysis. Responder analysis = % of patients in each group who respond, not mean differences between groups

149 views • 5 slides